CI - Cigna Corporation

NYSE - NYSE Delayed Price. Currency in USD
181.76
-1.52 (-0.83%)
At close: 4:01PM EDT
Stock chart is not supported by your current browser
Previous Close183.28
Open183.40
Bid170.20 x 1100
Ask186.30 x 900
Day's Range180.13 - 183.82
52 Week Range163.02 - 227.13
Volume2,085,266
Avg. Volume2,149,159
Market Cap44.234B
Beta0.77
PE Ratio (TTM)17.72
EPS (TTM)10.26
Earnings DateNov 1, 2018
Forward Dividend & Yield0.04 (0.02%)
Ex-Dividend Date2018-03-09
1y Target Est222.59
Trade prices are not sourced from all markets
  • Reuters4 hours ago

    PRESS DIGEST- Wall Street Journal - Aug 14

    The following are the top stories in the Wall Street Journal. Reuters has not verified these stories and does not vouch for their accuracy. - Elon Musk said Saudi Arabia's sovereign-wealth fund has approached ...

  • Thomson Reuters StreetEvents5 hours ago

    Edited Transcript of CI earnings conference call or presentation 2-Aug-18 12:30pm GMT

    Q2 2018 Cigna Corp Earnings Call

  • The Wall Street Journal6 hours ago

    [$$] Icahn Backs Down on Cigna-Express Scripts Deal

    Carl Icahn no longer plans to solicit votes from Cigna Corp. shareholders against the health insurer’s $54 billion deal to buy Express Scripts Holding Co. after two proxy-advisory firms recommended shareholders support the deal, the billionaire activist investor said in a statement Monday. It called his opposition “misguided and shortsighted” in a statement last week.

  • Reuters8 hours ago

    Icahn reverses position on Cigna-Express Scripts deal

    Icahn's comments come after proxy advisory firms Glass Lewis & Co and Institutional Shareholder Services Inc (ISS), as well as hedge fund Glenview Capital Management, extended their support for the deal. "In light of the ISS and Glass Lewis recommendations in favor of the Cigna/Express Scripts transaction and the significant stockholder overlap between the two companies, we have informed the SEC (U.S. Securities and Exchange Commission) that we no longer intend to solicit proxies to vote against the transaction," Icahn said in a statement. The billionaire investor, who has a long position on Cigna and a short position on Express Scripts, has been vocal in his criticism of the deal and last week said Cigna (CI.N) was overpaying for Express Scripts (ESRX.O).

  • Icahn reverses position on Cigna-Express Scripts deal
    Reuters8 hours ago

    Icahn reverses position on Cigna-Express Scripts deal

    Icahn's comments come after proxy advisory firms Glass Lewis & Co and Institutional Shareholder Services Inc (ISS), as well as hedge fund Glenview Capital Management, extended their support for the deal. "In light of the ISS and Glass Lewis recommendations in favour of the Cigna/Express Scripts transaction and the significant stockholder overlap between the two companies, we have informed the SEC (U.S. Securities and Exchange Commission) that we no longer intend to solicit proxies to vote against the transaction," Icahn said in a statement.

  • Bloomberg9 hours ago

    Icahn Drops Fight to Block Cigna's Express Scripts Takeover

    Activist investor Carl Icahn has dropped his fight to block Cigna Corp.’s $54 billion acquisition of Express Scripts Holding Co. after two prominent shareholder advisory firms came out in support of the deal. Institutional Shareholder Services Inc. and Glass Lewis & Co. last week urged Cigna’s investors to support the takeover, saying it made sense from a financial and strategic perspective. Icahn had opposed the deal, saying it would be a “travesty” if it were to proceed.

  • Express Scripts-Cigna pending merger praised by proxy advisory firms
    American City Business Journals21 hours ago

    Express Scripts-Cigna pending merger praised by proxy advisory firms

    Two proxy advisory firms have recommended that Express Scripts' and Cigna's shareholders vote in favor of their pending $54 billion merger.

  • PR Newswire22 hours ago

    Leading Independent Proxy Advisory Firm Glass Lewis Recommends Express Scripts Stockholders Vote "FOR" Merger Agreement with Cigna

    ST. LOUIS, Aug. 13, 2018 /PRNewswire/ -- Express Scripts (ESRX) today announced that Glass, Lewis & Co., LLC ("Glass Lewis"), a leading independent proxy advisory firm, has recommended that Express Scripts stockholders vote "FOR" Express Scripts' merger agreement with Cigna (CI) at Express Scripts' upcoming special meeting of stockholders scheduled for August 24, 2018.

  • Reuters22 hours ago

    Cigna-Express Scripts deal gets backing from another proxy firm

    Billionaire activist investor Carl Icahn, who owns shares in Cigna, opposes the deal. On Friday, Institutional Shareholder Services Inc (ISS) had extended support to the deal. Glass Lewis found the merger to be strategically and financially compelling for Cigna shareholders, the health insurer said in a statement.

  • Reuters22 hours ago

    Cigna-Express Scripts deal gets backing from another proxy firm

    Cigna Corp said Glass Lewis & Co on Monday recommended its shareholders vote in favour for the proposed $52 billion acquisition of pharmacy benefits manager Express Scripts, the second proxy advisory firm to support the deal. Billionaire activist investor Carl Icahn, who owns shares in Cigna, opposes the deal. On Friday, Institutional Shareholder Services Inc (ISS) had extended support to the deal.

  • Business Wire23 hours ago

    A Second Leading Independent Proxy Advisory Firm Glass Lewis Recommends Cigna Shareholders Vote “FOR” Acquisition of Express Scripts

    Cigna Corporation (CI) (“Cigna” or the “Company”) announced that independent proxy advisory firm Glass Lewis & Co. (“Glass Lewis”) has joined Institutional Shareholder Services ("ISS") in recommending that Cigna shareholders vote to approve the proposed acquisition of Express Scripts (ESRX) at the Company's upcoming special meeting scheduled for August 24, 2018.

  • Icahn Dealt Another Blow as Glass Lewis Supports Cigna Deal
    Bloomberg3 days ago

    Icahn Dealt Another Blow as Glass Lewis Supports Cigna Deal

    Another prominent shareholder advisory firm has come out in support of Cigna Corp.’s $54 billion takeover of pharmacy benefits manager Express Scripts Holding Co., dealing another blow to activist investor Carl Icahn’s efforts to block the transaction. “We find the proposed merger both strategically and financially compelling, structured in a reasonable manner from a valuation standpoint for Cigna shareholders,” Glass Lewis said in its report late Friday. Brian Henry, a spokesman for Express Scripts, said the company was pleased with the results of Glass Lewis report.

  • The Wall Street Journal3 days ago

    [$$] ISS Backs Cigna-Express Scripts Deal, in Blow to Carl Icahn

    Carl Icahn’s effort to find enough allies to block Cigna Corp.’s $54 billion proposed purchase of pharmacy-benefit manager Express Scripts Holding Co. just got a little harder. Institutional Shareholder Services, one of two major proxy-advisory firms, is recommending shareholders of the health insurer and Express Scripts support the deal in a vote later this month, according to reports ISS clients received Friday that were viewed by The Wall Street Journal. The news sent shares of Express Scripts up 3.8% to $84.90 Friday morning, as the odds the takeover will be completed appeared to improve.

  • Associated Press4 days ago

    Key shareholder adviser backs Cigna-Express Scripts deal

    Cigna's plan to buy pharmacy benefit manager Express Scripts for around $52 billion has received a big endorsement a few days after activist investor Carl Icahn urged shareholders to reject it. The proxy ...

  • PR Newswire4 days ago

    Leading Proxy Advisory Firm ISS Recommends Express Scripts Stockholders Vote "FOR" Merger with Cigna

    ST. LOUIS, Aug. 10, 2018 /PRNewswire/ -- Express Scripts (ESRX) today announced that Institutional Shareholder Services Inc. ("ISS"), a leading independent proxy advisory firm, has recommended that Express Scripts stockholders vote "FOR" Express Scripts' merger agreement with Cigna (CI) at Express Scripts' upcoming special meeting of stockholders scheduled for August 24, 2018. "We are pleased that ISS recognizes the highly attractive value this transaction delivers to Express Scripts' stockholders," said Tim Wentworth, President and Chief Executive Officer, Express Scripts.

  • Business Wire4 days ago

    Leading Independent Proxy Advisory Firm ISS Recommends Cigna Shareholders Vote “For” Acquisition of Express Scripts

    Cigna Corporation (CI) (“Cigna” or the “Company”) announced that leading independent corporate governance and proxy advisory firm Institutional Shareholder Services (“ISS”) has concluded its analysis and today issued a recommendation that Cigna shareholders vote to approve the proposed acquisition of Express Scripts (ESRX) at the Company's upcoming special meeting scheduled for August 24, 2018. “We are pleased with the recommendation of ISS that Cigna shareholders support the recommendation of our Board and vote in favor of our merger with Express Scripts,” said David M. Cordani, Cigna President and Chief Executive Officer.

  • Glenview Scores Win over Carl Icahn as ISS Supports Cigna’s Deal Plan
    Bloomberg4 days ago

    Glenview Scores Win over Carl Icahn as ISS Supports Cigna’s Deal Plan

    The recommendation is at odds with billionaire investor Carl Icahn’s efforts to drum up investor opposition to the takeover of the pharmacy benefit manager ahead of an Aug. 24 shareholder vote. Institutional Shareholder Services Inc. urged investors to support the deal. “For investors with exposure to both sides of this equation, the value proposition of a combination is straightforward: the potential benefits of the combination outweigh the risks, especially given that these risks are, to some degree, unavoidable,” ISS said in the report.

  • CNBC4 days ago

    Cigna's acquisition of Express Scripts get vote of confidence from investor advisor ISS

    Proxy advisor Institutional Shareholder Services recommends shareholders approve Cigna's acquisition of Express Scripts. ISS said the transaction is financially compelling, and one that would give the combined company immediate scale with strong cash flow generation. Carl Icahn published a searing letter Tuesday opposing Cigna's $54 billion acquisition of pharmacy benefit manager Express Scripts.

  • Motley Fool4 days ago

    Carl Icahn Fires Shots at Express Scripts

    Billionaire activist-investor Carl Icahn thinks Cigna’s planned tie-up with Express Scripts is a big blunder.

  • Business Wire5 days ago

    Cigna Reiterates Continued Support for Proposed Merger with Express Scripts

    Cigna Corporation (CI) (“Cigna” or the “Company”) issued the following letter to stockholders in response to the second letter released by Carl C. Icahn about the Company’s proposed merger with Express Scripts Holding Company (ESRX) (“Express Scripts”). This morning Carl Icahn released a second letter in opposition of our combination with Express Scripts.

  • Glenview, Icahn Face Off Over Cigna/Express Scripts Deal
    Bloomberg5 days ago

    Glenview, Icahn Face Off Over Cigna/Express Scripts Deal

    Activist investor Carl Icahn’s push to derail Cigna Corp.’s proposed $54 billion takeover of pharmacy-benefits firm Express Scripts Holding Co. isn’t convincing one big shareholder. Glenview Capital Management LLC publicly backed the deal on Thursday in a letter to Cigna shareholders, urging other investors to do the same, saying the company is actually paying a cheap price for Express Scripts compared with similar takeovers in the past. “Sensationalist headlines and intentionally misleading assertions from those with conflicting interests and limited analysis should not carry more weight than balanced diligence,” Glenview said in 13-page letter.

  • Reuters5 days ago

    Glenview backs Cigna-Express Scripts deal after Icahn criticism

    Glenview, which has been an investor in Cigna for a decade, said it has nearly $1.3 billion stake in Cigna and Express Scripts, split almost evenly between the two companies. The hedge fund said it purchased a significant stake in Express Scripts and increased its investment in Cigna following the $52 billion deal announcement in March.

  • Glenview backs Cigna-Express Scripts deal after Icahn criticism
    Reuters5 days ago

    Glenview backs Cigna-Express Scripts deal after Icahn criticism

    Glenview, which has been an investor in Cigna for a decade, said it has nearly $1.3 billion stake in Cigna and Express Scripts, split almost evenly between the two companies. The hedge fund said it purchased a significant stake in Express Scripts and increased its investment in Cigna following the $52 billion deal announcement in March. "Contrary to the sensationalist rhetoric of those pushing personal agendas, PBMs combat drug price inflation and encourage better pharmaceutical adherence," Glenview said, adding the deal would strengthen Cigna's growth prospects.

  • CNBC5 days ago

    Glenview's Larry Robbins takes on Carl Icahn, defends Cigna-Express Scripts deal

    Glenview Capital's Larry Robbins is supporting Cigna's deal to acquire Express Scripts. Billionaire activist and Cigna shareholder Carl Icahn called the deal a "$60 billion folly" this week. "Mr. Icahn has been misled by misinformation fed to him by analysts with short-term personal agendas," Robbins said.

  • Long-term Cigna Shareholder Glenview Capital Submits Open Letter to Shareholders in Support of Cigna / Express Scripts Transaction
    PR Newswire5 days ago

    Long-term Cigna Shareholder Glenview Capital Submits Open Letter to Shareholders in Support of Cigna / Express Scripts Transaction

    Cigna projects an incremental $253 per member of annual medical cost savings, the vast majority of which will flow to customers and payors, for customers who use managed care and PBM services from the newly combined Cigna / Express Scripts, an estimate corroborated by other leading industry players.